|
|
|
 |
| Location: Home -
Products - API Intermediates - API Intermediates
|
Gemcitabine Base
| Catalogue No. : |
C15008 |
| Product Name: |
Gemcitabine Base |
| Synonym: |
LY 188011; NSC 613327; Zefei |
| Chemical Name: |
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;2'-Deoxy-2',2'-difluorocytidine;2'-Deoxy-2',2'-difluoro-D-cytidine;2',2'-Difluoro-2'-deoxycytidine |
| CAS No. : |
95058-81-4 |
| Structure : |
|
| Molecular Formula: |
C9H11F2N3O4 |
| Molecular Weight: |
263.20 |
| Solubility: |
DMSO ≥12mg/mL Water <1.2mg/mL |
| Purity: |
>99% |
| Usage: |
Gemcitabine is a widely used antitumor agents in both clinics and research labs. It is an antineoplastic agent and antimetabolite. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Gemcitabine inhibits proliferation BxPC-3 pancreatic cancer cell line with IC50 of 0.06 μM. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
